From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
Vyvanse (lisdexamfetamine) and its generic version are expected to be equally effective when they contain the same active ingredient at the same dosage, as the FDA requires generic medications to demonstrate bioequivalence to brand-name versions, meaning they must deliver the same amount of active ingredient to the bloodstream at the same rate 1.
Key Points to Consider
- The metabolic process of lisdexamfetamine to its active form (dextroamphetamine) occurs consistently regardless of whether the medication comes from the brand-name or generic manufacturer, suggesting similar effectiveness 2.
- Patients should maintain their prescribed dosage when switching between brand and generic versions, which typically range from 20mg to 70mg daily taken in the morning.
- Some patients may notice subtle differences in inactive ingredients, but these generally don't affect the medication's therapeutic benefits for ADHD or binge eating disorder.
- It's essential to note that Vyvanse remains under patent protection in the United States, so true generic lisdexamfetamine is not yet widely available in the US market, but when generic versions do become fully available, patients can expect similar effectiveness.
Clinical Evidence
- A study published in 2020 discussed the pharmacological properties and clinical effects of lisdexamfetamine, highlighting its efficacy in treating ADHD 2.
- Other studies have compared the efficacy of lisdexamfetamine with other medications, such as atomoxetine, and found lisdexamfetamine to be effective in treating ADHD 3, 4, 5.
Conclusion Not Applicable - Direct Answer Only
In summary, based on the available evidence, Vyvanse (lisdexamfetamine) and its generic version are expected to be equally effective when they contain the same active ingredient at the same dosage, as supported by the most recent study 2.